Notal Vision
Eileen Lauer, MS, currently serves as a Clinical Project Manager at Notal Vision since November 2022. Previously, Eileen held the position of Clinical Project Manager at Gyroscope Therapeutics from March 2021 to October 2022 and served as an Associate Clinical Study Manager and Clinical Studies Associate at Astellas Pharma US between August 2018 and March 2021. Eileen's career includes roles as a Clinical Studies Specialist at AbbVie and Project Manager for the Clinical Research Program at the American College of Surgeons. Eileen began a clinical research career as a Clinical Research Coordinator at Rush University Medical Center and has interned at the Rehabilitation Institute of Chicago and the University of Chicago. Eileen earned a Master's degree in Clinical Research from Rush University and a Bachelor of Science in Biomedical/Medical Engineering from Saint Louis University.
This person is not in any offices
Notal Vision
Notal Vision is a patient-centric ophthalmic remote monitoring services provider extending retinal disease monitoring from the clinic to the home, providing physicians with remote monitoring services to support their patient care between office visits. With a proven approach to home-based, self-operated diagnostics, AI-enabled data analysis, and patient engagement, we help preserve patients’ vision. The Notal Vision Monitoring Center is a remote, Medicare credentialed ophthalmic provider and the epicenter of patient engagement. Led by practicing ophthalmologists and supported by certified ophthalmic professionals, the Monitoring Center offers a comprehensive nationwide age-related macular degeneration (AMD) home monitoring service for referred patients. The ForeseeHome® AMD Monitoring Program helps physicians detect the conversion to wet AMD early, leading to earlier treatment intervention and better visual outcomes. Our Home OCT pipeline technology will provide patient-initiated retinal OCT scans to support the management of patients with neovascular retinal diseases, complementing existing in-office imaging and standard of care treatments as well as emerging longer acting drugs and drug delivery systems.